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The IVF-stem cell interfaceAmong the many ethical issues raised by human
embryonic stem cell derivation, one of the most
urgent and practical, but often overlooked, is its
relationship to the clinical practice of in vitro
fertilisation (IVF). Since the late 1970s when it was
first successfully performed in the UK, IVF has
expanded rapidly, with over 2 million babies born
worldwide by 2005. Although it has been associ-
ated with some increased risks, such as elevated
rates of multiple births, and despite failing for
a majority of couples who undertake it, IVF is
a widely accepted, often celebrated, and largely
uncontroversial technology that continues to ex-
pand, for example through the increasing use of
preimplantation genetic diagnosis (PGD).
More recently, IVF has become the primary
source of embryos donated by patients to the
prominent and fast-paced field of stem cell re-
search, and this has important consequences for
both sides of what can be described as the IVF-
stem cell interface. As IVF clinics come into
greater proximity with stem cell derivation labo-
ratories, and as the connections between assisted
Conception Unit (ACU) teams and research scien-
tists intensify in the effort to derive and character-
ise viable hES lines, challenging practical issues are
arising that require careful consideration and for-
ward thinking. Although these practical issues are
often dwarfed by more sensational topics, such as
whether or not humans should be cloned, or the
spectre of human-animal chimeras, future evalua-
tions of the professional standards established in
the stem cell field at this early stage may owe
more to the amount of care taken over specific,
practical, and technical tasks than adherence to
abstract ethical principles that are often difficult
to define.
The controversy surrounding the allegedly
fraudulent conduct of South Korea’s Woo Suk
Hwang have, paradoxically, increased pressure on1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. Pub
doi:10.1016/j.ijsu.2006.02.008the scientific community to demonstrate the very
highest standards of ethical practice in the context
of hES cell derivation, while simultaneously illus-
trating how easily scientific evidence, materials,
and documents can be forged. If this is true of
a highly technical DNA scan, what are the impli-
cations for the credibility of informed consent
forms? The very same extensive documentation
that made Hwang’s research appear to comply to
the highest ethical standards, but which was
revealed to have been faked, demonstrates that
documentation alone is never a sufficient guaran-
tee of veracity. A paper trail may be only that.
These issues of what are commonly referred to
as accountability and transparency point to the
need for robust informed consent procedures for
egg and embryo donation to stem cell research
that are more than ‘paper-tight’, but what will
these consist of? Informed consent was originally
developed for procedures such as surgical inter-
ventions that posed a risk to the life or health of
the individual, and was intended to protect
patients against the pressures of medical pater-
nalism. Over time, informed consent has been
expanded to cover everything from liability pro-
tection for clinicians to organ donation. Unsurpris-
ingly, the expansion of informed consent has been
accompanied by criticisms of its ‘empty ethics’
from those who claim it has become more of
a panacea than an actual form of protection, and
more an exercise in ‘box ticking’ than actual
communication between doctor and patient.1
In the context of embryo donation, informed
consent is complicated by several features, such as
the fact that two people must give their consent as
a couple if the embryo is to be donated to research
(whereas informed consent was initially envisaged
as individual). Studies show wide divergences in
couples’ willingness to donate their embryos to
research in general,2e4 and this finding has beenlished by Elsevier Ltd. All rights reserved.
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stem cell research in particular.5,6 This is not sur-
prising given that embryos produced in the context
of IVF are complex embodiments of reproductive
hope, reproductive labour, and often reproductive
loss7 (Figs. 1 and 2).
The question of what could be considered ‘good
consenting practice’ in the context of embryo
donation to stem cell research must confront
additional uncharted issues. In 2002, the Medical
Research Council (MRC) in the UK awarded funds to
seven leading stem cell research teams to support
collaboration with assisted conception units with
the aim of improving, among other things, in-
formed consent procedures for embryo donation.
Fourteen human embryonic stem cell coordinators
were appointed to devise protocols for procedures
which could serve as the basis for greater national
coordination on issues ranging from derivation
methods and laboratory standards to patient in-
formation and feedback. In December 2003 addi-
tional money was provided by the MRC to enable
representatives from the original seven plus three
additional teams to form a national network of
Human Embryonic Stem Cell Coordinators (hESCCO)
to meet twice a year for three years to improve
communication and collaboration between centres
dispersed across the UK, from Aberdeen to London
(http://www.ukstemcell.net).
Many of the issues faced by the hESCCO mem-
bership have not been raised in the context of
informed consent before. For example, since an
hES line is potentially immortal, the question of
what kind of feedback might be either offered to,
or desired by, patients in the future is open-ended.
Figure 1 High-quality embryos showing even develop-
ment are selected for IVF treatment (courtesy of Sue
Pickering).Should patients be made aware if a potentially
damaging genetic mutation is discovered in a cell
line made from their embryo? Should this informa-
tion only be made available if the condition is
treatable? Is it realistic to agree to offer such
feedback, which might, in theory, also be desired
by future generations of the patients’ offspring?
Traceability poses similar challenges. Under EU law
all human tissue products must be traceable for
public health reasons. Potential embryo donors must
consequently agree to reversible anonymitydin
some peoples’ opinion a contradiction in terms.
Reliable documentation systems must be estab-
lished to keep track of donorsdpotentially in
perpetuity. All of these complex considerations
must be clearly communicated to patients as part
of a time-consuming process that requires consid-
erable dedication on the part of practitioners, and
patience from couples who are understandably
prone to ‘consent fatigue’.
The list of challenging issues raised by embryo
donation to stem cell research also includes
commercialisation. Not only must potential donors
be made aware of the potential for hES lines from
their embryos to be commercialised, and that they
may be sold to private companies, but also that
there is, in reality, little control over what hap-
pens to a cell line when it is purchased by, for
example, an overseas biotechnology company and
travels to another part of the world, which may or
may not have regulation similar to that in the UK.
Although it is the policy of the UK Stem Cell Bank
Figure 2 Poor quality embryos with uneven develop-
ment which are not viable for clinical purposes may be
donated to research (courtesy of Sue Pickering).
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of provenance for any lines that are deposited,
including their ethical sourcing, and to restrict
access to the deposited lines to legitimate appli-
cants who are assessed by their Steering Commit-
tee, some assurances are difficult to provide. In
response, for example, to the question of whether
lines may be used in the future to make artificial
gametes, the possibility of conditional consen-
tingda practice deemed unacceptable in the
context of blood donationdis currently under
consideration by UK regulatory bodies such as the
HFEA (Figs. 3 and 4).
In sum, it is clear that the stem cell field
continues to raise challenging ethical questions
that will require an evolving process of innovation
at the level of practice as well as principle. Like
the complex questions of GMP arising at the IVF-
stem cell interface, for which new definitions of
quality control and monitoring are being devised,
so too is this the site of ongoing innovation in
definitions of ‘best consenting practice’. Patients,
who often share the ‘more box ticking’ view of the
myriad informed consent forms they complete
during even a single IVF cycle, frequently ask
challenging questions for which it is difficult to
provide definite answers.
This is fortunate, because an active, critical
dialogue is essential to robust informed consent
procedures, and to the development of effective
patient information materials. Especially at this
early stage in the process of devising standards of
best practice in the context of informed consent
for embryo donation to stem cell research, diffi-
cult questions should be welcomed, openly de-
bated, and valued because of the genuine
uncertainties they reveal. Literally papering over
the difficult practical questions raised by this
Figure 3 The WT3 stem cell line, derived at King’s,
was the first in the UK (courtesy of Stephen Minger).unique context of tissue donation with overly
reassuring patient information leaflets, or euphe-
mistic informed consent forms, will significantly
compromise the opportunity to learn more from
patients directly about their hopes, fears, doubts,
expectations, and direct experience of thinking
through the many issues raised by this important
and highly emotive field.
Empirical research on patent perceptions of
embryo donation to stem cell research, and on
the informed consent procedures used in this
context, is thus very sensibly a priority of the UK
hESCCO network, through which some intriguing
findings have already been revealed in a prelimi-
nary study. For example, although, as the polls
would predict, UK patients’ rates of willingness to
donate embryos to stem cell research are as high
as 70%, this does not correlate positively with
increased understanding of stem cells. Indeed, in
a recent questionnaire-based study based at the
Guy’s and St Thomas’ Centre for PGD in London,
the percentage of patients who had no knowledge
of what a stem cell was but were willing to donate
was twice as high as those who did have such
knowledge, and this pattern was almost exactly
matched by the reverse effect among those pa-
tients who were unwilling to donateda 50% higher
percentage of whom answered ‘yes’ to the ques-
tion ‘Do you know what a stem cell is?’.8
As has been evident in the wake of ‘Hwang-
gate’, public scepticism is inevitably heightened
by such dramatic episodes of scientific fraud, but
underlying hopes for medical progress through
Figure 4 An embryo with a large inner cell mass (ICM)
from which cell lines are derived (courtesy of Sue
Pickering).
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in many cases seemingly unquenchable.9 Though it
may seem counterintuitive to claim that there are,
indeed, grounds for welcoming public scepticism
as a means of protecting the integrity and improv-
ing the quality of public debate over controversial
areas of science, there is some evidence to support
this view.10,11 Such evidence is also increasingly
finding its way into public policy.12 In the most re-
cent recommendations to emerge from the Austra-
lian Reports on the Prohibition of Human Cloning
Act 2002 and the Research Involving Human Em-
bryos Act 2002, for example, data collection on
public perceptions of human embryonic stem cell
research, and public outreach via a website are
recommended as a priority13 (Fig. 5).
An area that will, and should be, the subject of
more vigorous debate in both the UK and Australia,
where national guidelines on the use of embryos
are well established, is the ethical and ‘best
practice’ sourcing of what are referred to as fresh,
high-quality eggs, preferably from young and
healthy donors. While such ‘top of the range’
eggs are increasingly seen to be essential for
successful derivation of cell lines, sourcing them
comes into conflict with the de facto, if not strictly
de jure, practice of protecting patients’ interests
by only designating clinically non-viable eggs as
Figure 5 Human embryonic stem cell banking under
GMP conditions (courtesy of UK Stem Cell Bank).‘surplus’, ‘spare’ or ‘extra’. The turn, fuelled by
the momentum of the stem cell field, toward
asking patients who have large numbers of eggs
to donate some to research responds at one level
to many patients’ explicitly expressed wishes to
‘give something back’ to medical science. On the
other hand, this practice, and its kindred ilk in
‘egg sharing for research’, through which patients
are remunerated for their donations via reduced
cost of IVF treatment, will have to be carefully
monitored in light of the self-evident conflicts of
interest they raise.
Another debate that is likely to become more
prominent at the IVFestem cell interface is the
riskebenefit ratio of greater physical proximity
between Assisted Conception Units (ACUs) and hES
derivation laboratories. In the UK, five centres
have been awarded funds from the MRC to upgrade
their ACU laboratory facilities with the aim of
producing stem cells under GMP conditions. While
such upgraded facilities will ensure more efficient
and productive use of donated embryos, a concern
raised by specialists is that the clean room re-
quirements of the derivation laboratory are not
the ideal environment for embryos intended for
IVF, and thus that extra care must be taken ‘to
maintain gametes and embryos under the optimum
environmental conditions’14 (Fig. 6).
Conversely, a potential benefit of the increasing
proximity between IVF and stem cell research is the
possibility for improvements to IVF procedures, for
example through devising more sophisticated
means of assessing embryo quality and viability
prior to implantation. Were such benefits to be
seen to be flowing back into IVF, some of the risks
associated with the ‘derivation orientation’ pro-
duced by the excitement over stem cells might be
Figure 6 Human embryonic stem cell propagation may
be improved with higher-quality embryos (courtesy of
UK Stem Cell Bank).
90 Editorialoffset. Crucial to this process, however,will be open
discussion of the pressures that affect the IVF-stem
cell interface, and the measures that can be taken
to reduce their accompanying risks. Both detailed
empirical engagement with patient perceptions of
embryo donation to stem cell research, and support
for collaboration among practitioners in the effort
to establish best practice in this field will be key
components of addressing the practical ethics
which are the bottom line in the highly competitive
and fast-paced context of hES cell derivation.
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